RxDoctor Payments Data

Anthony Filoso, MD

Urology · Salem, MANPI 1679532469

Payments from drug & device makers

$3,111in general payments, 2019–2025

Across 128 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$482
  • Astellas Pharma US Inc$451
  • Boston Scientific$339
  • AbbVie$258
  • Johnson & Johnson$243
  • Ferring Pharmaceuticals Inc.$185
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,02097%
  • Education$903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,111 in reported general payments places this provider in the 60th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$217,924
Medicare patients
729
Services billed
3,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron275$149,769
GemtesaVibegron91$64,907
ElmironPentosan Polysulfate Sodium28$39,189
Tamsulosin Hcl1,733$27,039
Finasteride779$9,318
Mirabegron ErMirabegron13$6,858
Trospium Chloride77$6,181
Silodosin53$5,007
Fesoterodine Fumarate ErFesoterodine Fumarate47$4,854
Solifenacin Succinate120$3,596
Potassium Citrate ErPotassium Citrate36$3,398
Testosterone43$3,272
Bethanechol Chloride73$3,135
Oxybutynin Chloride ErOxybutynin Chloride99$2,445
Oxybutynin Chloride105$2,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$451$149,769275 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 327 urology providers in Massachusetts.

Other urology in Salem

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →